Cagrilintide

Cagrilintide Molecular Structure & Chemical Properties

Cagrilintide represents a significant advancement in peptide-based weight management research, emerging from intensive medicinal chemistry efforts to overcome the inherent instability challenges of amylin analogs. Developed at through structure-activity relationship studies, this long-acting acylated amylin analog has completed phase 3 clinical trials with results published in major medical journals in 2025. Unlike its predecessor pramlintide, which requires multiple daily injections due to a short half-life, cagrilintide’s unique lipidated structure enables once-weekly dosing through reversible albumin binding. This peptide acts as a dual agonist at both amylin receptors (AMYR) and the calcitonin receptor (CTR), a property that distinguishes it from selective amylin analogs and may contribute to its observed efficacy in clinical studies.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide incorporates key structural modifications including N-terminal lipidation with a C20 fatty diacid via an alpha-glutamyl spacer, three amino acid substitutions (N14E, V17R, P37Y) compared to pramlintide, and strategic proline residues (positions 25, 28, 29) that dramatically reduce the amyloid fibril formation propensity characteristic of native amylin.

Cagrilintide Mechanism of Action

Cagrilintide peptide exerts its biological effects through dual activation of amylin receptors and calcitonin receptors, working through complementary pathways in both homeostatic and hedonic appetite regulation centers of the brain. Research demonstrates that the peptide functions as a non-selective agonist, activating AMY1R, AMY2R, AMY3R (amylin receptor subtypes formed by CTR complexed with receptor activity-modifying proteins RAMP1-3), and CTR itself. This multi-receptor profile distinguishes cagrilintide from selective amylin analogs and appears critical for its efficacy, as studies in receptor knockout models confirm that both AMY1R and AMY3R are required for the full weight-reducing effects.

Primary Receptor Activation Pathways

Amylin Receptor Signaling – Central Appetite Suppression

Cagrilintide lowers body weight through mechanisms dependent on AMY1R and AMY3R activation in the central nervous system. The peptide acts on neurons in the area postrema of the hindbrain and the hypothalamus to induce satiety and reduce food intake. Key aspects of this pathway include:

• Direct CNS effects on homeostatic appetite regulation centers
• Activation of brainstem neurons that relay satiety signals
• Hypothalamic pathway modulation affecting energy expenditure
• Sustained signaling despite rapid plasma clearance, suggesting tissue retention or persistent pathway activation

Structural studies reveal that cagrilintide binds to amylin receptors through specific molecular interactions that stabilize the active receptor conformation, enabling prolonged agonist activity compared to endogenous amylin.

Calcitonin Receptor Co-Activation – Enhanced Metabolic Effects

Unlike selective amylin analogs, cagrilintide maintains significant activity at the calcitonin receptor (CTR), which may contribute to its superior efficacy. Research indicates:

• Non-selective CTR and AMYR agonism produces greater weight loss than AMYR-selective compounds
• CTR activation may enhance metabolic rate and energy expenditure
• Synergistic effects between AMYR and CTR pathways in weight regulation
• Distinct receptor dynamics compared to salmon calcitonin, avoiding receptor downregulation

The dual AMYR/CTR agonist profile appears optimal for obesity treatment, with clinical data supporting superior efficacy compared to AMYR-selective approaches.

Gastric Emptying Delay – Peripheral Satiety Enhancement

Through activation of neurons in the brain, cagrilintide slows gastric emptying and induces satiety. This peripheral mechanism complements central appetite suppression:

• Delayed gastric transit prolongs nutrient absorption and satiety signals
• Reduced meal size through enhanced fullness perception
• Glucagon suppression in postprandial state
• Complementary effects with GLP-1 pathway when co-administered with GLP1

Albumin Binding – Protracted Pharmacokinetic Profile

The C20 fatty diacid modification enables reversible albumin binding, which is fundamental to cagrilintide’s long duration of action:

• Strong albumin association protects peptide from rapid renal clearance
• Reversible binding allows tissue distribution to target sites
• Similar mechanism to GLP1’s albumin-binding strategy
• Extended half-life enabling once-weekly dosing convenience

Cagrilintide Research Applications & Key Findings

Obesity and Weight Management Research

Clinical Weight Loss Studies

In the REDEFINE 1 phase 3 trial, cagrilintide-GLP1 combination resulted in 20.4% mean weight loss over 68 weeks compared to 3.0% with placebo. When studied as monotherapy in the same trial:

• 11.5% mean weight loss with cagrilintide 2.4 mg alone versus 3.0% placebo at 68 weeks
• 60% of participants receiving combination therapy achieved at least 20% weight loss
• 23% achieved 30% or more weight loss with combination therapy
• Superior outcomes compared to either agent alone, demonstrating complementary mechanisms

Phase 2 dose-finding studies established that cagrilintide 2.4 mg resulted in 10% bodyweight reduction versus 3% with placebo after 26 weeks.

Dose-Response and Optimization Studies

Phase 1b trials investigated cagrilintide doses from 0.16 mg to 4.5 mg weekly, establishing pharmacokinetic profiles and tolerability:

• Proportional exposure with increasing doses from 0.16-4.5 mg
• Optimal therapeutic dose identified as 2.4 mg for combination therapy
• Higher monotherapy doses (up to 4.5 mg) studied for enhanced efficacy
• Dose-dependent effects on appetite suppression and weight loss

Type 2 Diabetes Research

Glycemic Control Studies

The REDEFINE 2 trial in adults with type 2 diabetes and obesity showed 13.7% mean weight reduction with cagrilintide-GLP1 versus 3.4% with placebo:

• 73.5% of patients achieved glycated hemoglobin levels of 6.5% or less
• Dual benefits on both weight and glycemic parameters
• Improved continuous glucose monitoring metrics
• Complementary mechanisms with GLP-1 receptor agonist

Phase 2 studies in type 2 diabetes demonstrated superior HbA1c reductions with combination therapy compared to either agent alone, with mean reductions exceeding those seen with current standard treatments.

Cardiovascular and Metabolic Research

Cardiometabolic Outcomes

REDEFINE 1 demonstrated significant improvements in systolic blood pressure, waist circumference, and lipid profiles:

• Blood pressure reductions observed with treatment
• Waist circumference decreases reflecting visceral fat loss
• Lipid parameter improvements including triglycerides and VLDL-C
• 88% of participants with prediabetes achieved normoglycemia

The ongoing REDEFINE 3 cardiovascular outcomes trial (7,000 participants) is investigating major adverse cardiovascular event (MACE) reduction in adults with established cardiovascular disease.

Receptor Pharmacology Research

Mechanistic and Selectivity Studies

Cagrilintide demonstrates potent, non-selective agonism of CTR and all three AMY receptor subtypes in functional cellular assays:

• EC50 values in nanomolar range across AMYR subtypes
• Non-selective profile distinguishes it from AMYR-selective analogs
• Cryo-EM structural studies reveal distinct binding mechanisms compared to other calcitonin family peptides
• Receptor residence time and signaling kinetics differ from salmon calcitonin

Cagrilintide Pharmacokinetics & Metabolism

Absorption & Distribution

Cagrilintide exhibits slow absorption after subcutaneous administration, with median time to maximum concentration (tmax) of 24-72 hours following doses of 0.16-4.5 mg. Following weekly subcutaneous injection in clinical studies:

• Proportional exposure across the therapeutic dose range
• Steady-state achievement after multiple weekly doses
• Subcutaneous bioavailability enables once-weekly dosing
• Tissue distribution likely mediated by albumin binding and release

Maximum plasma concentration (Cmax) ranges from 6.14 nmol/L to 170 nmol/L with doses of 0.16-4.5 mg, with higher doses used in monotherapy compared to combination regimens.

Metabolism & Elimination

The half-life in clinical studies was determined to be 159-195 hours, with subsequent studies confirming an approximate 8-day (180-hour) half-life. Metabolic characteristics include:

• Half-life of approximately 184 hours (7.7 days) at the 2.4 mg dose
• Proteolytic degradation likely occurs through peptidase activity
• Sequential beta-oxidation of the fatty diacid side chain
• Metabolite elimination via renal and hepatic pathways

The lipidation strategy with fatty diacids provides extended half-life through reversible albumin binding, similar to the mechanism employed by GLP1.

Excretion Pathways

Elimination occurs through typical peptide clearance mechanisms:

• Proteolytic cleavage of the peptide backbone generates metabolites
• Renal excretion of degradation products
• No accumulation observed in chronic dosing studies
• Clearance and volume of distribution remain consistent across doses

Plasma clearance and volume of distribution for cagrilintide were similar across all treatment groups studied, indicating predictable pharmacokinetic behavior across the therapeutic range.

Cagrilintide Research Protocols & Administration

Dosing in Published Research

Clinical trials have employed escalation protocols to optimize tolerability while achieving therapeutic doses:

• Initial dose: 0.25 mg weekly for weeks 1-4, escalating to 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16)
• Maintenance dose: 2.4 mg weekly starting at week 17 for combination therapy
• Monotherapy range: 0.3 mg to 4.5 mg weekly studied in phase 2 trials
• Combination therapy: 2.4 mg cagrilintide with 2.4 mg GLP1 in phase 3 studies

Important: These are investigational doses used in human clinical trials. Research protocols employ careful dose escalation over 16 weeks to minimize gastrointestinal adverse events. Animal study doses cannot be extrapolated to humans due to substantial species differences in receptor distribution, peptide metabolism, and pharmacodynamic responses.

Administration Routes in Research

Clinical development has focused on subcutaneous delivery:

• Subcutaneous injection – Once-weekly administration in all clinical trials; optimal absorption profile
• Injection sites – Abdomen, thigh, or upper arm rotation standard in protocols
• Formulation pH – Low pH formulation for stability and solubility
• Co-administration – Compatible with GLP1 in fixed-dose combination studies

Study Populations in Clinical Research

Human clinical trials have enrolled diverse populations:

• Phase 3 obesity trials – Adults with BMI greater than or equal to 30, or BMI greater than or equal to 27 with comorbidities (REDEFINE 1: 3,417 participants)
• Phase 3 diabetes trials – Adults with type 2 diabetes and obesity (REDEFINE 2: 1,206 participants)
• Phase 2 studies – Dose-finding in obesity, type 2 diabetes, and combination therapy populations
• Cardiovascular outcomes – REDEFINE 3 enrolling 7,000 participants with established CVD

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite extensive phase 3 clinical data published in 2025, several important questions remain under investigation regarding long-term outcomes and optimal use.

Long-Term Efficacy and Safety

While 68-week data from REDEFINE trials provide substantial evidence, longer-term questions persist:

• Duration beyond 68 weeks requires further study to establish maintenance of weight loss
• Cardiovascular outcomes data pending from the ongoing REDEFINE 3 trial (expected completion in future years)
• Long-term safety profile beyond the studied durations incompletely characterized
• Weight regain patterns after discontinuation not fully elucidated

Mechanistic Understanding Gaps

Fundamental aspects of cagrilintide’s mechanism warrant further investigation:

• Relative contribution of CTR versus AMYR activation to clinical effects remains incompletely defined
• Tissue-specific receptor expression and activity in humans requires clarification
• Optimal receptor selectivity profile for various patient populations unknown
• Interaction effects with other metabolic pathways not fully characterized

Clinical Application Questions

Practical considerations for therapeutic use require additional research:

• Patient selection criteria for monotherapy versus combination approaches
• Comparative effectiveness versus other obesity medications in real-world settings
• Management strategies for gastrointestinal adverse events
• Combination potential with medications beyond GLP1

Regulatory & Clinical Development Status

FDA and Regulatory Position

Cagrilintide remains investigational as of September 2025:

• Not FDA-approved for any indication as of current date
• Phase 3 programs completed with results published in New England Journal of Medicine June 2025
• Dedicated RENEW phase 3 program for cagrilintide monotherapy announced for initiation Q4 2025
• Regulatory submissions anticipated following completion of development programs
• Combination therapy (CagriSema) also under development for potential future approval

WADA Status

Information on World Anti-Doping Agency classification not specified in available research literature. Athletes should consult current WADA prohibited substance lists and seek guidance from anti-doping authorities regarding investigational peptides.

Research Classification: Cagrilintide is currently available only for clinical research under investigational protocols. It is not approved for medical use, not available for prescription, and not intended for general research use outside approved clinical trials. All clinical research must be conducted under appropriate regulatory oversight with institutional review board approval and informed consent.

References

1. Kruse, T., Hansen, J.L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A.M.K., Jeppesen, C.B., Dornonville de la Cour, C., Clausen, T.R., Johansson, E., Fulle, S., Skyggebjerg, R.B., & Raun, K. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(15), 11183-11194. PubMed
   
2. Fletcher, M.M., Keov, P., Truong, T.T., Mennen, G., Hick, C.A., Zhao, P., Furness, S.G.B., Kruse, T., Clausen, T.R., Wootten, D., & Sexton, P.M. (2021). AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Journal of Pharmacology and Experimental Therapeutics, 377(3), 417-440. PubMed
   
3. Lau, D.C.W., Erichsen, L., Francisco, A.M., Satylganova, A., le Roux, C.W., McGowan, B., Pedersen, S.D., Pietiläinen, K.H., Rubino, D., & Batterham, R.L. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160-2172. PubMed
   
4. Enebo, L.B., Berthelsen, K.K., Kankam, M., Lund, M.T., Rubino, D.M., Satylganova, A., & Lau, D.C.W. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with GLP1 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet, 397(10286), 1736-1748. PubMed
   
5. Frias, J.P., Hsia, S., Erichsen, L., Gosak, M., Heitmann, M., Kallenbach, K., Larsen, M., Nauck, M.A., Nilsson, B., Rosenstock, J., Sørrig, R., Usman, M., & Davies, M.J. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly GLP1 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet, 402(10398), 720-730. PubMed
   
6. Garvey, W.T., Blüher, M., Osorto Contreras, C.K., Davies, M.J., Lehmann, E.W., Pietiläinen, K.H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J.P.H. (2025). Coadministered Cagrilintide and GLP1 in Adults with Overweight or Obesity. New England Journal of Medicine, 393(7), 635-647. PubMed
   
7. Davies, M.J., Bajaj, H.S., Broholm, C., Eliasen, A., Garvey, W.T., le Roux, C.W., Lingvay, I., Lyndgaard, C.B., Rosenstock, J., & Pedersen, S.D. (2025). Cagrilintide-GLP1 in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(7), 648-659. PubMed
   
8. Dehestani, B., Stratford, N.R., & le Roux, C.W. (2021). Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome, 30(4), 320-325. PubMed
   
9. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications (2025). Research demonstrating molecular basis for cagrilintide’s non-selective receptor activation.
10. D’Ascanio, A.M., Mullally, J.A., & Frishman, W.H. (2024). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review, 32(1), 83-90. PubMed
    
11. Gabe, M.B.N., Sparre-Ulrich, A.H., Pedersen, M.F., Gasbjerg, L.S., Iepsen, E.W., Hartmann, B., Christensen, M.B., Vilsbøll, T., Holst, J.J., Rosenkilde, M.M., & Knop, F.K. (2024). Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity and Metabolism, 27(1), 322-330.
12. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. PMC article demonstrating mechanism of action through specific amylin receptor subtypes in knockout mouse models.
13. Palani, G., Dey, A., Saraf, S., Yadav, N., Karthikeyan, A., Mishra, V., Singh, K.P., & Kesharwani, P. (2024). Efficacy and Safety of Cagrilintide Alone and in Combination with GLP1 (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Journal of Obesity & Metabolic Syndrome, 33(4), 314-329. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Cagrilintide is an investigational compound intended for clinical research use only under appropriate regulatory oversight.